Efficient and targeted delivery of siRNA in vivo

RNA interference (RNAi) has been regarded as a revolutionary tool for manipulating target biological processes as well as an emerging and promising therapeutic strategy. In contrast to the tangible and obvious effectiveness of RNAi in vitro, silencing target gene expression in vivo using small interfering RNA (siRNA) has been a very challenging task due to multiscale barriers, including rapid excretion, low stability in blood serum, nonspecific accumulation in tissues, poor cellular uptake and inefficient intracellular release. This minireview introduces major challenges in achieving efficient siRNA delivery in vivo and discusses recent advances in overcoming them using chemically modified siRNA, viral siRNA vectors and nonviral siRNA carriers. Enhanced specificity and efficiency of RNAi in vivo via selective accumulations in desired tissues, specific binding to target cells and facilitated intracellular trafficking are also commonly attempted utilizing targeting moieties, cell‐penetrating peptides, fusogenic peptides and stimuli‐responsive polymers. Overall, the crucial roles of the interdisciplinary approaches to optimizing RNAi in vivo, by efficiently and specifically delivering siRNA to target tissues and cells, are highlighted.

[1]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Michaela Scherr,et al.  Gene silencing mediated by small interfering RNAs in mammalian cells. , 2003, Current medicinal chemistry.

[3]  J. Lieberman,et al.  The silent treatment: siRNAs as small molecule drugs , 2006, Gene Therapy.

[4]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[5]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[6]  Leaf Huang,et al.  Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[7]  K Mechtler,et al.  The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. , 1994, The Journal of biological chemistry.

[8]  C. Plank,et al.  Application of membrane-active peptides for drug and gene delivery across cellular membranes. , 1998, Advanced drug delivery reviews.

[9]  Phillip A. Sharp,et al.  The RNAi revolution , 2004, Nature.

[10]  D. Sørensen,et al.  Cationic liposome-mediated delivery of siRNAs in adult mice. , 2003, Biochemical and biophysical research communications.

[11]  G. Hannon,et al.  Unlocking the potential of the human genome with RNA interference , 2004, Nature.

[12]  Shiroh Futaki,et al.  A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[13]  J. Heyes,et al.  Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Sanyog Jain,et al.  Liposomes Modified with Cyclic RGD Peptide for Tumor Targeting , 2004, Journal of drug targeting.

[15]  S Moein Moghimi,et al.  A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  T. Honda,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D 1 as an Anti-Inflammatory Target , 2022 .

[17]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[18]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[19]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[20]  Robert J. Lee,et al.  Folate receptor-targeted liposomes as vectors for therapeutic agents. , 2002, Biotechnology annual review.

[21]  Leaf Huang,et al.  Lipid-protamine-DNA-mediated antigen delivery. , 2005, Current drug delivery.

[22]  Priti Kumar,et al.  Interfering antiviral immunity: application, subversion, hope? , 2006, Trends in Immunology.

[23]  P. Tan,et al.  Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat , 2005, Gene Therapy.

[24]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[25]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[26]  N. Kosaka,et al.  Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. , 2004, Nucleic acids research.

[27]  M. Breunig,et al.  Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Kazunori Kataoka,et al.  Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. , 2005, Journal of the American Chemical Society.

[29]  Seppo Ylä-Herttuala,et al.  Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain , 2006, The journal of gene medicine.

[30]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[31]  Stephen P. Fox,et al.  The Design and Exogenous Delivery of siRNA for Post-transcriptional Gene Silencing , 2004, Journal of drug targeting.

[32]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[33]  D. Thompson,et al.  Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[34]  F. Kirchhoff.  Silencing HIV-1 In Vivo , 2008, Cell.

[35]  L. Chaloin,et al.  A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. , 1997, Nucleic acids research.

[36]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[37]  J. Petricciani,et al.  Incorporation of exogenous DNA into mammalian chromosomes , 1974, Nature.

[38]  P. Chien,et al.  Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo , 2005, Cancer Gene Therapy.

[39]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[40]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[41]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[42]  K. Alexander,et al.  RNA interference using boranophosphate siRNAs: structure-activity relationships. , 2004, Nucleic acids research.

[43]  S. Akhtar,et al.  Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. , 2007, Advanced drug delivery reviews.

[44]  J. Kjems,et al.  Chitosan/siRNA Nanoparticle-mediated TNF-α Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[46]  A. Aigner,et al.  RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. , 2006, Human gene therapy.

[47]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[48]  T. Park,et al.  Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. , 2006, Bioconjugate chemistry.

[49]  Ming Wu,et al.  Designing highly active siRNAs for therapeutic applications , 2010, The FEBS journal.

[50]  A. Klippel,et al.  Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. , 2003, Nucleic acids research.

[51]  L. Ellis,et al.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.

[52]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[53]  R. Tomanin,et al.  Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. , 2004, Current gene therapy.

[54]  T. Irimura,et al.  Antitumor Activity of Small Interfering RNA/Cationic Liposome Complex in Mouse Models of Cancer , 2004, Clinical Cancer Research.

[55]  S Moein Moghimi,et al.  Low and high molecular weight poly(l‐lysine)s/poly(l‐lysine)–DNA complexes initiate mitochondrial‐mediated apoptosis differently , 2005, FEBS letters.

[56]  M. Amarzguioui,et al.  An algorithm for selection of functional siRNA sequences. , 2004, Biochemical and biophysical research communications.

[57]  Kinam Park,et al.  Polycation gene delivery systems: escape from endosomes to cytosol , 2003, The Journal of pharmacy and pharmacology.

[58]  T. Ohtsuki,et al.  Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. , 2008, Bioconjugate chemistry.

[59]  M. Katze,et al.  Functional expression and RNA binding analysis of the interferon-induced, double-stranded RNA-activated, 68,000-Mr protein kinase in a cell-free system , 1991, Molecular and cellular biology.

[60]  P. Silver,et al.  Therapeutic potential of retroviral RNAi vectors , 2004, Expert opinion on biological therapy.

[61]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[62]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[63]  N. Kim,et al.  RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[64]  M. Radosz,et al.  Virion-mimicking nanocapsules from pH-controlled hierarchical self-assembly for gene delivery. , 2008, Angewandte Chemie.

[65]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[66]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[67]  R. Juliano,et al.  Biological barriers to therapy with antisense and siRNA oligonucleotides. , 2009, Molecular pharmaceutics.

[68]  Steven F Dowdy,et al.  Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. , 2007, Advanced drug delivery reviews.

[69]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  P. Opolon,et al.  Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.

[71]  M. Kay,et al.  Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? , 2007, The Journal of clinical investigation.

[72]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[73]  Kenneth A Howard,et al.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[74]  V. Torchilin,et al.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[76]  B. Polisky,et al.  Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication , 2005, Hepatology.

[77]  T. Tamiya,et al.  The NH2 Terminus of Influenza Virus Hemagglutinin-2 Subunit Peptides Enhances the Antitumor Potency of Polyarginine-mediated p53 Protein Transduction* , 2005, Journal of Biological Chemistry.

[78]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[79]  Sangsoo Kim,et al.  Adenovirus‐mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo , 2006, Hepatology.

[80]  Irena Melnikova,et al.  RNA-based therapies , 2007, Nature Reviews Drug Discovery.

[81]  C. Chung,et al.  The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. , 2010, Biomaterials.

[82]  Xin-guo Jiang,et al.  Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. , 2010, Human gene therapy.

[83]  T. Niidome,et al.  In vivo siRNA delivery with dendritic poly(L-lysine) for the treatment of hypercholesterolemia. , 2009, Molecular bioSystems.

[84]  Patty J. Lee,et al.  Small Interfering RNA Targeting Heme Oxygenase-1 Enhances Ischemia-Reperfusion-induced Lung Apoptosis* , 2004, Journal of Biological Chemistry.

[85]  Anastasia Khvorova,et al.  Off-target effects by siRNA can induce toxic phenotype. , 2006, RNA.

[86]  Mouldy Sioud,et al.  Gene silencing by systemic delivery of synthetic siRNAs in adult mice. , 2003, Journal of molecular biology.

[87]  M. Woodle,et al.  Modulation of angiogenesis with siRNA inhibitors for novel therapeutics , 2005, Trends in Molecular Medicine.

[88]  B. Cullen,et al.  RNA interference in human cells is restricted to the cytoplasm. , 2002, RNA.

[89]  A. Prochiantz,et al.  The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.

[90]  M. Manoharan,et al.  Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. , 2009, Oligonucleotides.

[91]  S. Tsao,et al.  Utility of Epstein–Barr virus-encoded small RNA promoters for driving the expression of fusion transcripts harboring short hairpin RNAs , 2008, Gene Therapy.

[92]  S. Pun,et al.  Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles. , 2008, Bioconjugate chemistry.

[93]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[94]  S. Sabbioni,et al.  Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA , 2007, Gene Therapy.

[95]  L. Medina-Kauwe,et al.  Intracellular trafficking of nonviral vectors , 2005, Gene Therapy.

[96]  S. Reske,et al.  Gene silencing by adenovirus‐delivered siRNA , 2003, FEBS letters.

[97]  John J. Rossi,et al.  The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.

[98]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[99]  Thomas Tuschl,et al.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. , 2003, Antisense & nucleic acid drug development.

[100]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[101]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[102]  Jean-Luc Coll,et al.  Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth , 2009, Nucleic acids research.

[103]  R. Schiffelers,et al.  Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. , 2007, International journal of pharmaceutics.

[104]  Yu-Kyoung Oh,et al.  siRNA conjugate delivery systems. , 2009, Bioconjugate chemistry.

[105]  R. Kodet,et al.  Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours , 2004, Neuropathology and applied neurobiology.

[106]  B. Lebleu,et al.  Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells , 2005, Nucleic acids research.

[107]  Priscille Brodin,et al.  A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.

[108]  F. Natt,et al.  siRNA relieves chronic neuropathic pain. , 2004, Nucleic acids research.

[109]  S. W. Kim,et al.  Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[110]  Qing Ge,et al.  Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Anton P. McCaffrey,et al.  In vivo activity of nuclease-resistant siRNAs. , 2004, RNA.

[112]  Raymond M Schiffelers,et al.  Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. , 2004, The American journal of pathology.

[113]  K. G. Rajeev,et al.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.

[114]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[115]  J. Leonard,et al.  Staying on message: design principles for controlling nonspecific responses to siRNA , 2010, The FEBS journal.

[116]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[117]  S. Kaul,et al.  Vectors for RNA interference. , 2004, Current opinion in molecular therapeutics.

[118]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[119]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[120]  M. Ogris,et al.  Acetal linked oligoethylenimines for use as pH-sensitive gene carriers. , 2008, Bioconjugate chemistry.

[121]  T. Park,et al.  siRNA delivery systems for cancer treatment. , 2009, Advanced drug delivery reviews.

[122]  Young Jik Kwon,et al.  Acid-responsive linear polyethylenimine for efficient, specific, and biocompatible siRNA delivery. , 2009, Bioconjugate chemistry.

[123]  J. Behr,et al.  Lipid‐mediated siRNA delivery down‐regulates exogenous gene expression in the mouse brain at picomolar levels , 2005, The journal of gene medicine.

[124]  J. Whitton,et al.  Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity , 2002, Gene Therapy.

[125]  Matthias John,et al.  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.

[126]  A. Aigner,et al.  RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo , 2005, Gene Therapy.

[127]  V. Zurawski,et al.  Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. , 1992, Cancer research.

[128]  P. Guo,et al.  Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells , 2006, Gene Therapy.